Is interim 18 f-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

Is interim 18 f-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

E. Etchebehere, A.E. Brito, K. Kairemo, E. Rohren, J. Araujo, H. Macapinlac

ARTIGO

Inglês

[O PET/CT interim com fluoreto- 18 F é capaz de predizer desfechos após a terapia com rádio-223?]

To dichloride ( 223 RaCl 2 ) therapy is able to identify patients that will not respond to treatment. We retrospectively reviewed 34 histologically confirmed cases of hormone-refractory prostate cancer with bone metastasis in patients submitted to 223 RaCl 2 therapy. All of the patients underwent...

Avaliar se o PET/CT interim com fluoreto-18F após a terceira dose da terapia com dicloreto de rádio-223 (223Ra) é capaz de identificar pacientes que não responderão ao tratamento. Revisamos, retrospectivamente, 34 pacientes com diagnóstico histológico de câncer de próstata refratários a...

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP

Aberto

Is interim 18 f-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

E. Etchebehere, A.E. Brito, K. Kairemo, E. Rohren, J. Araujo, H. Macapinlac


										

Is interim 18 f-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

E. Etchebehere, A.E. Brito, K. Kairemo, E. Rohren, J. Araujo, H. Macapinlac

    Fontes

    Radiologia brasileira

    Vol. 52, no. 1 (Jan./Feb., 2019), p. 33-40